Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus

Table 1 Number of hypoglycemia episodes and glycemic variability in experimental animals

Group	Control	IpMI	IaMI	GLP1pMI	GLP1aMI	GLP1pMI + IaMI
Hypoglycemia episodes (n)	0	5	3	1	2	1
Glycemic variability	4.48 ± 0.74	6.29 ± 0.9a	5.57 ± 1.3	3.79 ± 0.65a	3.60 ± 0.65a	3.00 ± 0.42a

^aP < 0.05, vs control group. Control: Rats with T2DM without therapy; IpMI: Rats treated with insulin prior to MI; IaMI: Rats treated with insulin after MI; GLP1pMI: Rats treated with GLP-1a prior to MI; GLP1aMI: Rats treated with GLP-1a after MI; GLP1pMI + IaMI: Rats treated with GLP-1a prior to MI and with insulin after MI.

Table 2 Mortality of rats expressed as percentages with different antihyperglycemic therapies

Group	1Control(n = 8)	2IpMI(n = 16)	3IaMI(n = 12)	4GLP1pMI(n = 12)	5GLP1aMI(n = 12)	6GLP1pMI + IaMI (n = 10)
Ratio of surviving to dead rats (% of deaths)	5/3 (37.5%)	8/8 (50%)	7/5 (41.6%)	8/4 (30 %)	8/4 (30 %)	8/2 (20%)

Control: Rats with T2DM without therapy; IpMI: Rats treated with insulin prior to MI; IaMI: Rats treated with insulin after MI; GLP1pMI: Rats treated with GLP-1a prior to MI; GLP1aMI: Rats treated with GLP-1a after MI; GLP1pMI + IaMI: Rats treated with GLP-1a prior to MI and with insulin after MI.